Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study

AuthorsBurnham, SC.
Bourgeat, Pierrick
Doré, Vincent
Savage, G.
Brown, B.
Laws, S.
Maruff, P.
Salvado, O.
Ames, D.
Martins, RN.
Masters, CL.
Rowe, CC.
Villemagne, VL.
TypeJournal Article (Original Research)
JournalThe Lancet Neurology
Year of Publication2016
URLhttp://www.thelancet.com/journals/laneur/article/PIIS1474-4422(16)30125-9/abstract
DOIhttp://dx.doi.org/10.1016/S1474-4422(16)30125-9
AbstractSummaryBackground Brain amyloid β (Aβ) deposition and neurodegeneration have been documented in about 50-60% of cognitively healthy elderly individuals (aged 60 years or older). The long-term cognitive consequences of the presence of Alzheimer's disease pathology and neurodegeneration, and whether they have an independent or synergistic effect on cognition, are unclear. We aimed to characterise the long-term clinical and cognitive trajectories of healthy elderly individuals using a two-marker (Alzheimer's disease pathology and neurodegeneration) imaging construct. Methods Between Nov 3, 2006, and Nov 25, 2014, 573 cognitively healthy individuals in Melbourne and Perth, Australia, (mean age 73·1 years [SD 6·2]; 58% women) were enrolled in the Australian Imaging, Biomarker and Lifestyle (AIBL) study. Alzheimer's disease pathology (A) was determined by measuring Aβ deposition by PET, and neurodegeneration (N) was established by measuring hippocampal volume using MRI. Individuals were categorised as A−N−, A+N−, A+N+, or suspected non-Alzheimer's disease pathophysiology (A−N+, SNAP). Clinical progression, hippocampal volume, standard neuropsychological tests, and domain-specific and global cognitive composite scores were assessed over 6 years of follow-up. Linear mixed effect models and a Cox proportional hazards model of survival were used to evaluate, compare, and contrast the clinical, cognitive, and volumetric trajectories of patients in the four AN categories. Findings 50 (9%) healthy individuals were classified as A+N+, 87 (15%) as A+N−, 310 (54%) as A−N−, and 126 (22%) as SNAP. APOE ε4 was more frequent in participants in the A+N+ (27; 54%) and A+N− (42; 48%) groups than in the A−N− (66; 21%) and SNAP groups (23; 18%). The A+N− and A+N+ groups had significantly faster cognitive decline than the A−N− group (0·08 SD per year for AIBL-Preclinical AD Cognitive Composite [PACC]; p<0·0001; and 0·25; p<0·0001; respectively). The A +N+ group also had faster hippocampal atrophy than the A−N− group (0·04 cm3 per year; p=0·02). The SNAP group generally did not show significant decline over time compared with the A−N− group (0·03 SD per year [p=0·19] for AIBL-PACC and a 0·02 cm3 per year increase [p=0·16] for hippocampal volume), although SNAP was sometimes associated with lower baseline cognitive scores (0·20 SD less than A−N− for AIBL-PACC). Within the follow-up, 24% (n=12) of individuals in the A+N+ group and 16% (n=14) in the A+N− group progressed to amnestic mild cognitive impairment or Alzheimer's disease, compared with 9% (n=11) in the SNAP group. Interpretation Brain amyloidosis, a surrogate marker of Alzheimer's disease pathology, is a risk factor for cognitive decline and for progression from preclinical stages to symptomatic stages of the disease, with neurodegeneration acting as a compounding factor. However, neurodegeneration alone does not confer a significantly different risk of cognitive decline from that in the group with neither brain amyloidosis or neurodegeneration. Funding CSIRO Flagship Collaboration Fund and the Science and Industry Endowment Fund (SIEF), National Health and Medical Research Council, the Dementia Collaborative Research Centres programme, McCusker Alzheimer's Research Foundation, and Operational Infrastructure Support from the Government of Victoria.

http://www.ibas.org.au/what-we-do/publications/3872845


< More publications



ARIELARIEL

Interstitial lung disease (ILD) is a chronic lung condition that causes stiff lungs and restricts sufferers from taking a deep breath. Exercise in a gym, such as walking or riding a bike, can help make...

SHiQ - COSAQSHIQ - COSAQ

Each year in Australia 260 people sustain a SCI, with over half losing full function in their arms and legs (quadriplegia). In addition to the primary disability, there is a very high rate of Obstructive...

Notch monitoring in sleepNOTCH MONITORING IN SLEEP

Sleep apnea is a condition where breathing is abnormal during sleep. There are two main forms of sleep apnea: obstructive and central. For obstructive sleep apnea, breathing is reduced because the airway...

Do you have Spinal cord injury? Tired?  Get treated!DO YOU HAVE SPINAL CORD INJURY? TIRED? GET TREATED!

Melbourne researchers have found that 80 percent of people with quadriplegic spinal injuries have sleep apnoea. It's having a big effect on their lives but they don't know they have it, and they don't know it can be treated.

World 1st heavy vehicle driver fatigue study releasedWORLD 1ST HEAVY VEHICLE DRIVER FATIGUE STUDY RELEASED

The National Transport Commission (NTC) and the Cooperative Research Centre for Alertness, Safety and Productivity (Alertness CRC) have released the results of what is hailed as a world-first study into heavy vehicle driver fatigue.

AAMRI Election Statement released on 25th March 2019AAMRI ELECTION STATEMENT RELEASED ON 25TH MARCH 2019

AAMRI released its election statement calling on politicians to commit to three main priorities: ensuring the MRFF reaches $20 billion by 2020-21, provide continued strong support for the NHMRC, and develop sustainable and rewarding career pathways.

Portrait unveiled at Canberra's Parliament HousePORTRAIT UNVEILED AT CANBERRA'S PARLIAMENT HOUSE

IBAS Director Anna Burke had barely got into the swing of her speech at the unveiling of her portrait at Canberra's Parliament House when the ringing of bells caused half her audience to hurry away.

Institute for Breathing and Sleep

Level 5, Harold Stokes Building, Austin Hospital
145 Studley Road
Heidelberg, Victoria, 3084

(03) 9496 5390

Email Us

Donate